Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.

Diabetes Ther · 2021 · PMC7994483 · PMID 33635502

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

EX enatide S tudy of C ardiovascular E vent L owering Trial (EXSCEL) showed nominally significant reduction in ACM (but not for CV death) [ 3 ]; for ACM these studies appear to suggest that exenatide may be associated with mortality postponement in a broad population and certainly does not appear to increase morality risk.

also in 7,732 other papers

did not reach statistical significanceno p-value reported

In the case of an SCCS, although throughout the study the associated effect of exenatide on both recurrent (DNS) and incident AP increased over time following exposure (as did both bounds of the 95% CIs), the effect estimates did not reach statistical significance (Tables 4.5 and S8.5) [ 30 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.